Guardant Health

GH48

$31.13arrow_drop_up22.38%$5.66

GH48

$31.13

arrow_drop_up22.38%$5.66

Performance History

Key Stats
Open	$29.02
Prev. Close	$25.29
EPS	-4.11
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	28.60	29.95
52 Week Range	15.81	37.04

Ratios







EPS	-4.11

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Guardant Health (GH)

Guardant Health Inc (GH) is a leading precision oncology company that is focused on changing the management of cancer by offering non-invasive liquid biopsies and advanced diagnostic tests. The company's flagship product is Guardant360, a comprehensive liquid biopsy test that analyzes circulating tumor DNA to provide valuable information about genomic alterations in a patient's cancer. This innovative technology enables oncologists to make more informed treatment decisions and monitor the effectiveness of therapies. With its non-invasive nature, Guardant360 offers a more convenient and accessible alternative to traditional tissue biopsies.

In addition to Guardant360, Guardant Health also offers other diagnostic tests, including GuardantOMNI, which provides comprehensive genomic profiling for advanced-stage cancer patients, and GuardantLUNAR, which is a groundbreaking test for early-stage cancer detection. These tests have the potential to revolutionize cancer care by enabling early detection, monitoring minimal residual disease, and guiding targeted therapy selection. Guardant Health's tests are supported by a robust data platform and deep expertise in genomic sequencing and analysis.

Websitecall_made

Sector: Healthcare
Industry: Diagnostics & Research
CEO: Dr. Helmy Eltoukhy Ph.D.
Headquarters: Palo Alto
Employees: 1793
Exchange: NASDAQ

Keep an eye on Guardant Health

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Guardant Health 's (GH) price per share?

The current price per share for Guardant Health (GH) is $31.14. The stock has seen a price change of $5.66 recently, indicating a 22.38% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Guardant Health (GH)?

For Guardant Health (GH), the 52-week high is $37.04, which is 18.97% from the current price. The 52-week low is $15.81, the current price is 96.93% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Guardant Health (GH) a growth stock?

Guardant Health (GH) has shown an average price growth of -3.17% over the past three years. It has received a score of 12 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Guardant Health as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Guardant Health (GH) stock price performance year to date (YTD)?

As of the latest data, Guardant Health (GH) has a year-to-date price change of 17.45%. Over the past month, the stock has experienced a price change of 45.83%. Over the last three months, the change has been -3.19%. Over the past six months, the figure is 63.01%. Looking at a longer horizon, the five-year price change stands at -51.84%.

help

Is Guardant Health (GH) a profitable company?

Guardant Health (GH) has a net income of -$479.45M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 59.74% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -56.6% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $563.95M, with a revenue growth rate of 25.45%, providing insight into the company's sales performance and growth. The gross profit is $336.9M. Operating income is noted at -$562.52M. Furthermore, the EBITDA is -$382.2M.

help

What is the market capitalization of Guardant Health (GH)?

Guardant Health (GH) has a market capitalization of $4.01B. The average daily trading volume is 31.7, indicating the stock's liquidity and investor engagement.

News

Why Guardant Health Stock Was the Picture of Health Today

Can This Beaten-Down Cathie Wood Stock Bounce Back?

LIQUID BIOPSY

CANCER DIAGNOSTICS

NEXT-GENERATION SEQUENCING

NORTH AMERICA

MARKET GROWTH

Sep 13, 2024

Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy Insights

Why Guardant Health Stock Just Crashed 10%

LABORATORY-DEVELOPED TESTS

LDTS

FDA REGULATIONS

CLINICAL LABORATORIES

DIAGNOSTIC SERVICES

DIAGNOSTIC PRODUCTS

Aug 15, 2024

Laboratory-Developed Tests (LDTs) World Market Forecast Report to 2028, with Coverage of the Effects of the FDA's New "Medical Devices: Laboratory Developed Tests" Rule, Passed in April 2024

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought